Pfizer Canada (NYSE:PFE) has warned Health Canada that there is a shortage of 0.3 mg EpiPen auto-injectors due to a manufacturing disruption.
The company, which licenses the emergency allergy treatment from Mylan (NSDQ:MYL), reported that the problem should be resolved by March 2.
Get the full story at our sister site, Drug Delivery Business News.
The post EpiPen shortage in Canada to last until March appeared first on MassDevice.